Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Welcome to Natera’s 2024 Third Quarter Financial Results ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

at the European Society for Medical Oncology (ESMO) conference in September 2024. The ESMO presentation further revealed statistically significant improvement in survival for this triple ...

Two of our key studies were highlighted during the 2024 ESMO Conference in Spain. First, an update on our work with the TRACERx consortium in the area of lung cancer was presented by Charlie Swanton.

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. At ...

Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz Director, Investor Relations. Please go ahead.

I would now like to turn the conference over to Alexa buffet from corporate communications ... The initial data we presented at ESMO GI in 2024 just a few months ago from the Cornell study highlights ...

Issuer: CureVac / Key word (s): Conference CureVac to Present at the 12th International mRNA Health Conference 04.11.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this ...

“Data presented recently at the ESMO, SITC and SNO congresses showed that 77% of evaluable ... is being presented at the 12th International mRNA Health Conference in Boston from November 11-14, 2024.

First patient dosed in Phase 1 clinical trial evaluating ZW171 in advanced mesothelin (MSLN)-expressing cancers Preclinical data presented on ...